NCT07021547

A Study of LY3867070 in Healthy Participants

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 196 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3867070	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2025-05-27
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2025-06-15
• Last updated: 2026-01-21

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study